logo-loader
viewInstem PLC

Instem seeing all clients place orders as healthcare market stays buoyant

Phil Reason, chief executive of healthcare AI software group Instem PLC (LON:INS), says business was strong across all areas of the group in the first six months of 2019.

Even a change from licences to a SaaS or pay-as you-use model has gone smoothly, he says, with cash inflows strong over the first six months.

Healthcare generally is very strong and that drives more people to Instem, said Reason.

The SEND platform, which helps companies present data to the US FDA in a consistent format, saw revenues double for example, though Reason says all clients are placing orders.

Instem is looking at acquisitions, particularly in the area of software for later-stage clinical trials.

Quick facts: Instem PLC

Price: 369 GBX

AIM:INS
Market: AIM
Market Cap: £60.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Instem PLC reports strong demand for its informatics services

Instem PLC's (LON:INS) chief scientific officer and head of its informatics arm Dr Gordon Smith Baxter tells Proactive London the value of new orders for the division has grown by 58% to £840,000. He says the firm's expansion into informatics is bringing them into contact with customers at an...

4 weeks, 1 day ago

2 min read